ABIO Stock: ARCA biopharma, Inc. Stock Price, Analysis & Insights
Get live abio stock price $28.80, comprehensive ARCA biopharma, Inc. stock analysis, charts, news, and expert forecast. Real-time abio stock data and investment insights.
Company Overview
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
Company Information
- CEO
- Thomas A. Keuer
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
Contact Information
- Website
- https://www.arcabio.com
- Address
- 10170 Church Ranch Way
- Country
- US
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 34.82M market capitalization
- Trading Volume: 290.85K shares traded today
- Price Range: 52-week range of $2.25 - $53.88
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for ARCA biopharma, Inc.
ARCA biopharma, Inc. (ABIO) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 34.82M, the company represents a significant player in its market. The stock is currently trading at $28.80 with a positivedaily change of 1052.00%.
The company's 3 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -4.90, beta of 0.90, and 52-week price range from $2.25 to $53.88when evaluating investment opportunities.
Why Invest in ARCA biopharma, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Thomas A. Keuer
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.